A Study of Attitudes About the Risk of Developing Type 2 Diabetes

Status Completed

Clinical Trial Summary

Diabetes mellitus (DM) type 2 is well recognized as a major cause of morbidity and mortality in the United States, as well as a significant contributor to health disparities within the population. Changes in demographic and lifestyle characteristics in the population have led to a progressive increase in the prevalence of both diabetes and impaired glucose tolerance (IGT), a precursor to DM type 2. Although pharmacologic interventions have proven to be successful in blocking the progression from IGT to DM, they have not been as effective as diet and exercise modification. Studies of behavioral interventions in IGT have focused on the outcomes of improved DM risk factors and decreased progression to DM, but have either required extensive interventions that lack applicability to the general population or have utilized more modest interventions with no effect on risk factors. These studies have not included impact evaluations to assess the effect of knowledge of IGT status on motivation to change and perceived risk. This study will assess the impact of knowledge of IGT on the likelihood of altering health-related behaviors, utilizing the Health Belief Model as a conceptual framework. Subjects will be randomized to one of four treatment arms, organized in a factorial design to (1) assess the impact of OGTT testing on motivation to change behaviors and (2) evaluate the efficacy of a novel educational intervention linked to patients' learning styles. This evaluation will determine whether OGTT testing is more beneficial as a cue to action to motivate behavior change than a multifactorial assessment of diabetes risk. Additionally, the improvement in health motivation after an educational intervention is expected to be enhanced when the educational method is tailored to the individual's preferred learning style. This information will provide the foundation for more efficient behavioral interventions for patients at high risk for DM type 2.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label

Related Conditions & MeSH terms

Prediabetic State

Clinical Trial Details

NCT number	NCT00323349
Study type	Interventional
Source	Eastern Virginia Medical School
Contact
Status	Completed
Phase	N/A
Start date	April 2003
Completion date	December 2004

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05424107` - A Mediterranean Intervention on Prediabetic Children	N/A
Recruiting	`NCT02681887` - Effect of Melatonin on Cardiometabolic Risk- FULL	Phase 3
Completed	`NCT04088461` - Effect of Linagliptin + Metformin on Patients Who do Not Achieve Normoglucemia With Metformine	Phase 4
Recruiting	`NCT02561377` - Effect of Resistance Training on Metabolic Control and Outcome in Prediabetes (NMR-based Metabonomics)	N/A
Completed	`NCT02678390` - Medium Chain Triglycerides and Aerobic Exercise on Ketone Production in Women With or Without Prediabetes	N/A
Completed	`NCT02551640` - Improving Physical Activity Through a mHealth Intervention in Cardio-metabolic Risk Patients	N/A
Completed	`NCT02459691` - Culturally-adapted Diabetes Prevention Lifestyle Intervention for Latinos (E-LITE Latinos)	N/A
Completed	`NCT01671293` - Multicomponent Telecare Model for Supporting Prediabetes Patients	N/A
Completed	`NCT01479933` - Glucose Metabolism Effects of Vitamin D Supplementation in Prediabetes	N/A
Completed	`NCT00960973` - The Effect of Vitamin K Supplementation on Glucose Metabolism	Phase 4
Completed	`NCT00455325` - Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)	Phase 2
Recruiting	`NCT05123963` - Restoring 24-hour Substrate Rhythmicity to Improve Glycemic Control by Timing of Lifestyle Factors	N/A
Recruiting	`NCT05340868` - Genetics of the Acute Response to Oral Semaglutide	N/A
Recruiting	`NCT04984421` - IMplementation of the Family Support PRogramme A Healthy School Start to Prevent OVErweight and Obesity (IMPROVE)	N/A
Recruiting	`NCT04131582` - Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes	Phase 3
Recruiting	`NCT04134650` - Effect of Low Dose Combination of Linagliptin + Metformin to Prevent Diabetes	Phase 3
Recruiting	`NCT05347030` - Acupuncture for Impaired Glucose Tolerance in Overweight/Obese Population	N/A
Completed	`NCT04074148` - Effectiveness of Diabetes Prevention Education Program on Diabetes Prevention Among Prediabetes Population in Nepal	N/A
Recruiting	`NCT05050266` - Enhancing Mental and Physical Health of Women Veterans	N/A
Completed	`NCT02684565` - Effects of Branch Chain Amino Acids on Glucose Tolerance in Obese Pre-Diabetic Subjects	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.